Author

Luisa Guidi 1

1 Complesso Integrato Columbus, Catholic University

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

CANCER AND INFLAMMATORY BOWEL DISEASE PHENOTYPE: A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Renata D'Inca', Claudio Papi, Luisa Spina, Erika Angelucci, Carmelina Petruzziello, Luisa Guidi, Anna Kohn, Filippo Mocciaro, Patrizia Alvisi, Alessandra Ruffa, Rita Monterubbianesi, Walter Fries, Gabriele Riegler, Marco Daperno, Fabiana Castiglione, Giovanna Condino

CHARACTERIZATION OF INCIDENT CASES OF CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS: RELATION WITH IMMUNOMODULATORY TREATMENTS AND DISEASE PHENOTYPE IN A PROSPECTIVE MULTICENTER MATCHED-PAIR IG-IBD STUDY

Livia Biancone, Giovanna Condino, Alessandro Armuzzi, Maria Scribano, Renata D'Incà, Claudio Papi, Luisa Spina, Luisa Guidi, Anna Kohn, Emma Calabrese, Carmelina Petruzziello, Sara Onali, Filippo Mocciaro, Rita Monterubbianesi, Patrizia Alvisi, Walter Fries, Gabriele Riegler, Irene Frankovic, Giovanna Margagnoni, Gianmic

CHARACTERIZATION OF INCIDENT CASES OF CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A MULTICENTER CASE-CONTROL STUDY

Livia Biancone, Carmelina Petruzziello, Alessandro Armuzzi, Anna Kohn, Renata D'Incà, Claudio Papi, Luisa Spina, Luisa Guidi, Maria Lia Scribano, Emma Calabrese, Giovanna Condino, Sara Onali, Filippo Mocciaro, Rita Monterubbianesi, Patrizia Alvisi, Walter Fries, Gabriele Riegler, Giovanna Margagnoni, Roberto Di Mitri, Gi

COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE: RISK FACTORS IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Renata D'Incà, Claudio Papi, Luisa Spina, Luisa Guidi, Filippo Moccisro, Patrizia Alvisi, Alessandra Ruffa, Benedetto Neri, Walter Fries, Gabriele Riegler, Marco Daperno, Fabiana Castiglione, Sara Renna, Stefano Festa, Emma Calabrese, Gianmichele Meucci, Francesca R

COMBINATION THERAPY PREDICTS LONG-TERM MUCOSAL HEALING IN MODERATE-TO-SEVERE ULCERATIVE COLITIS TREATED WITH ANTI TNF-?

Daniela Pugliese, Pietro Manuel Ferraro, Carla Felice, Gian Lodovico Rapaccini, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Giuseppe Privitera, Sara Onali, Daniela Pugliese, Sara Renna, Edoardo Savarino, Anna Viola, Davide Giuseppe Ribaldone, Andrea Buda, Cristina Bezzio, Gionata Fiorino, Massimo Claudio Fantini, Franco Scaldaferri, Luisa Guidi, Silvio Danese, Antonio Gasbarrini, Ambrogio Orlando, Alessandro Armuzzi

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Laura Parisio, Carlo Romano Settanni, Daniele Napolitano, Simone Varca, Elisa Schiavoni, Lucrezia Laterza, Loris Riccardo Lopetuso, Marco Pizzoferrato, Stefano Bibbò, Norma Alfieri, Luisa Guidi, Alfredo Papa, Antonio Gasbarrini, Alessandro Armuzzi, Daniela Pugliese, Franco Scaldaferri

Item 1 - 10 / 41
1
2 3 4 5